Welcome to MOLOGEN AG

Our research - for you. That means, we conduct research to develop highly effective drugs with few side effects and excellent tolerability. Our main focus is on oncology and severe infectious diseases.

We use latest expertise from the fields of molecular medicine and immunology to enable the human immune system to fight the disease or disease pathogen itself - an approach that we are promoting with great conviction.

Using our own, patent-protected technology platforms, we are able to produce highly effective and extremely well-tolerated drugs against diseases with high unmet medical need. 

Strategy program "NEXT LEVEL"

DR. MARIOLA SÖHNGEN CEO MOLOGEN AG

• "Next Level" of corporate development: strategy program with strong product and market orientation on key projects • Focus on lead product lefitolimod (MGN1703) and next-generation technology EnanDIM® • Streamlining of company organization • Commercialization activities to be stepped up via out-licensing [more]

Today, the Executive Board of MOLOGEN AG (ISIN DE0006637200/WKN 663720), with the consent of the supervisory board, decided to implement a strategy program to concentrate its business activities on the further development and commercialisation of its main product, i.e. lefitolimod (MGN1703) including the successor molecule EnanDIM®. [more]

Quarterly Statement as at 31 March 2016
Download PDF

Annual Report 2015
Download PDF

Strategy Program “Next level”

Press Release
Presentation
FAQ